SCHEMBL2393825

SCHEMBL2393825

NC(=O)C(F)(F)c1ccccc1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 2/20 0.48
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
KCNN4 O15554 3/20 0.42
SCN9A Q15858 5/20 0.41
SLC13A5 Q86YT5 1/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
SCN10A Q9Y5Y9 1/20 0.39
FGFR1 P11362 1/20 0.39
SRC P12931 1/20 0.39
FGFR2 P21802 1/20 0.39
FGFR4 P22455 1/20 0.39
FGFR3 P22607 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
KCNE1 P15382 1/20 0.38
KCNQ1 P51787 1/20 0.38
HNF4A P41235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2397461 0.85 ALDH1A1 (0.45) BCAT2ALDH1A1HPGDFFAR4SLC13A5
SCHEMBL2390403 0.84 KCNN4 (0.45) KCNN4SCN9ASCN10AFGFR1FGFR3
Urea SCHEMBL27881390 0.83 FFAR4 (0.54) BCAT2ALDH1A1HPGDFFAR4SCN9A
SCHEMBL2395495 0.82 SCN9A (0.47) HPGDSCN9ASCN10A
SCHEMBL9890797 0.80 KCNN4 (0.49) ALDH1A1HPGDKCNN4KCNE1KCNQ1
SCHEMBL28846137 0.77 KCNN4 (0.44) ALDH1A1HPGDFFAR4KCNN4PPARG
SCHEMBL9890796 0.77 PLK1 (0.48) BCAT2ALDH1A1HPGDFFAR4SLC13A5
SCHEMBL30087702 0.76 LMNA (0.46) ALDH1A1HPGDKCNN4KCNE1KCNQ1
SCHEMBL30087647 0.75 ALDH1A1 (0.45) ALDH1A1HPGDKCNN4KCNE1KCNQ1
SCHEMBL30087649 0.75 KCNN4 (0.59) ALDH1A1KCNN4KCNE1KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP claimed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US claimed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 BCAT2 248/4885ALDH1A1 576/4885HPGD 3524/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 BCAT2 248/4885ALDH1A1 576/4885HPGD 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.